Skip to main content
SpringerLink
Log in

Biomaterial-Based Modulation of Cancer

  • Chapter
  • First Online:
Biomaterials in Regenerative Medicine and the Immune System

  • 1109 Accesses

Abstract

Recent progress in our understanding of tumor biology, cell–matrix interactions, and immune response has facilitated the development of innovative biomaterials, therapeutic delivery, and tissue-engineering approaches to modulate cancer. In this chapter, we provide a summary of the recent developments and highlight the unique material-based approaches for tumor vascularization, targeted therapy, organoids for tumor microenvironment, and immunotherapy. We briefly discuss the immune microenvironment and checkpoints and how they play a role in tumor-mediated immune suppression. Finally, we provide an overview of challenges and future direction in biomaterials-based modulation of cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Society AC. http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2014/index. 2014. Accessed: Dec 15, 2014

  2. Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer. 2006;94(7):982–99.

    Article  Google Scholar 

  3. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24(18):2903–9.

    Article  Google Scholar 

  4. Gattinoni L, Powell DJ, Jr., Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol. 2006;6(5):383–93.

    Article  Google Scholar 

  5. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144(5):646–74.

    Article  Google Scholar 

  6. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100(1):57–70.

    Article  Google Scholar 

  7. Zimmer J. Immunotherapy: natural killers take on cancer. Nature. 2014;505(7484):483.

    Article  Google Scholar 

  8. Mittendorf EA, Sharma P. Mechanisms of T-cell inhibition: implications for cancer immunotherapy. Expert Rev Vaccines. 2010;9(1):89–105.

    Article  Google Scholar 

  9. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64.

    Article  Google Scholar 

  10. Bretscher P, Cohn M. A theory of self-nonself discrimination. Science. 1970;169(3950):1042–9.

    Article  Google Scholar 

  11. Lafferty KJ, Cunningham AJ. A new analysis of allogeneic interactions. Aust J Exp Biol Med Sci. 1975;53(1):27–42.

    Article  Google Scholar 

  12. Callahan MK, Wolchok JD. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol. 2013;94(1):41–53.

    Article  Google Scholar 

  13. Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol. 2006;90:297–339.

    Article  Google Scholar 

  14. Purwada A, Roy K, Singh A. Engineering vaccines and niches for immune modulation. Acta Biomaterialia. 2014;10(4):1728–40.

    Article  Google Scholar 

  15. Lipson EJ, Drake CG. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res. 2011;17(22):6958–62.

    Article  Google Scholar 

  16. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54.

    Article  Google Scholar 

  17. Brahmer JR. Immune checkpoint blockade: the hope for immunotherapy as a treatment of lung cancer? Semin Oncol. 2014;41(1):126–32.

    Article  Google Scholar 

  18. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167–75.

    Article  Google Scholar 

  19. Young DA, Lowe LD, Booth SS, Whitters MJ, Nicholson L, Kuchroo VK, et al. IL-4, IL-10, IL-13, and TGF-beta from an altered peptide ligand-specific Th2 cell clone down-regulate adoptive transfer of experimental autoimmune encephalomyelitis. J Immunol. 2000;164(7):3563–72.

    Article  Google Scholar 

  20. Singh A, Peppas NA. Hydrogels and scaffolds for immunomodulation. Adv Mater. 2014;26(38):6530–41.

    Article  Google Scholar 

  21. Orive G, Ali OA, Anitua E, Pedraz JL, Emerich DF. Biomaterial-based technologies for brain anti-cancer therapeutics and imaging. Biochim Biophys Acta. 2010;1806(1):96–107.

    Google Scholar 

  22. Devaud C, John LB, Westwood JA, Darcy PK, Kershaw MH. Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. Oncoimmunology 2013;2(8):e25961.

    Article  Google Scholar 

  23. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751–60.

    Article  Google Scholar 

  24. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther. 2008;83(5):761–9.

    Article  Google Scholar 

  25. Levy-Nissenbaum E, Radovic-Moreno AF, Wang AZ, Langer R, Farokhzad OC. Nanotechnology and aptamers: applications in drug delivery. Trends Biotechnol. 2008;26(8):442–9.

    Article  Google Scholar 

  26. Fischbach C, Chen R, Matsumoto T, Schmelzle T, Brugge JS, Polverini PJ, et al. Engineering tumors with 3D scaffolds. Nat Methods. 2007;4(10):855–60.

    Article  Google Scholar 

  27. Choi NW, Cabodi M, Held B, Gleghorn JP, Bonassar LJ, Stroock AD. Microfluidic scaffolds for tissue engineering. Nat Mater. 2007;6(11):908–15.

    Article  Google Scholar 

  28. Zheng Y, Chen J, Craven M, Choi NW, Totorica S, Diaz-Santana A, et al. In vitro microvessels for the study of angiogenesis and thrombosis. Proc Natl Acad Sci U S A. 2012;109(24):9342–7.

    Article  Google Scholar 

  29. Chaudhuri O, Koshy ST, Branco da Cunha C, Shin JW, Verbeke CS, Allison KH, et al. Extracellular matrix stiffness and composition jointly regulate the induction of malignant phenotypes in mammary epithelium. Nat Mater. 2014;13(10):970–8.

    Article  Google Scholar 

  30. Yamada KM, Cukierman E. Modeling tissue morphogenesis and cancer in 3D. Cell 2007;130(4):601–10.

    Article  Google Scholar 

  31. Hutmacher DW, Horch RE, Loessner D, Rizzi S, Sieh S, Reichert JC, et al. Translating tissue engineering technology platforms into cancer research. J Cell Mol Med. 2009;13(8A):1417–27.

    Article  Google Scholar 

  32. Holy CE, Shoichet MS, Davies JE. Engineering three-dimensional bone tissue in vitro using biodegradable scaffolds: investigating initial cell-seeding density and culture period. J Biomed Mater Res. 2000;51(3):376–82.

    Article  Google Scholar 

  33. Zhang S, Gelain F, Zhao X. Designer self-assembling peptide nanofiber scaffolds for 3D tissue cell cultures. Semin Cancer Biol. 2005;15(5):413–20.

    Article  Google Scholar 

  34. Patel RG, Purwada A, Cerchietti L, Inghirami G, Melnick A, Gaharwar AK, et al. Microscale bioadhesive hydrogel arrays for cell engineering applications. Cell Mol Bioeng. 2014;7(3):394–408.

    Article  Google Scholar 

  35. Cayrol F, Diaz Flaque MC, Fernando T, Yang SN, Sterle HA, Bolontrade M, et al. Integrin alphavbeta3 acting as membrane receptor for thyroid hormones mediates angiogenesis in malignant T cells. Blood 2015;125(5):841–51.

    Article  Google Scholar 

  36. Morgan JP, Delnero PF, Zheng Y, Verbridge SS, Chen J, Craven M, et al. Formation of microvascular networks in vitro. Nat Protoc. 2013;8(9):1820–36.

    Article  Google Scholar 

  37. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1(1):27–31.

    Article  Google Scholar 

  38. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407(6801):249–57.

    Article  Google Scholar 

  39. Risau W. Mechanisms of angiogenesis. Nature. 1997;386(6626):671–4.

    Article  Google Scholar 

  40. Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med. 1971;133(2):275–88.

    Article  Google Scholar 

  41. Sengupta S, Eavarone D, Capila I, Zhao G, Watson N, Kiziltepe T, et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature. 2005;436(7050):568–72.

    Article  Google Scholar 

  42. Alexis F, Pridgen EM, Langer R, Farokhzad OC. Nanoparticle technologies for cancer therapy. Handb Exp Pharmacol. 2010;(197):55–86.

    Google Scholar 

  43. Etheridge ML, Campbell SA, Erdman AG, Haynes CL, Wolf SM, McCullough J. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine. 2013;9(1):1–14.

    Article  Google Scholar 

  44. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev. 2002;54(5):631–51.

    Article  Google Scholar 

  45. Pannier AK, Shea LD. Controlled release systems for DNA delivery. Mol Ther. 2004;10(1):19–26.

    Article  Google Scholar 

  46. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65(1–2):271–84.

    Article  Google Scholar 

  47. Maeda H, Sawa T, Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release. 2001;74(1–3):47–61.

    Article  Google Scholar 

  48. Joshi N, Shirsath N, Singh A, Joshi KS, Banerjee R. Endogenous lung surfactant inspired pH responsive nanovesicle aerosols: pulmonary compatible and site-specific drug delivery in lung metastases. Sci Rep. 2014;4:7085.

    Article  Google Scholar 

  49. Danhier F, Feron O, Preat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release. 2010;148(2):135–46.

    Article  Google Scholar 

  50. Reichert JM, Valge-Archer VE. Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov. 2007;6(5):349–56.

    Article  Google Scholar 

  51. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer. 2002;2(10):750–63.

    Article  Google Scholar 

  52. Akinc A, Querbes W, De S, Qin J, Frank-Kamenetsky M, Jayaprakash KN, et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther. 2010;18(7):1357–64.

    Article  Google Scholar 

  53. Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci U S A. 2008;105(45):17356–61.

    Article  Google Scholar 

  54. Torchilin VP. Multifunctional nanocarriers. Adv Drug Deliv Rev. 2006;58(14):1532–55.

    Article  Google Scholar 

  55. Cheng Z, Al Zaki A, Hui JZ, Muzykantov VR, Tsourkas A. Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science. 2012;338(6109):903–10.

    Article  Google Scholar 

  56. Negussie AH, Miller JL, Reddy G, Drake SK, Wood BJ, Dreher MR. Synthesis and in vitro evaluation of cyclic NGR peptide targeted thermally sensitive liposome. J Control Release. 2010;143(2):265–73.

    Article  Google Scholar 

  57. Sawant RM, Hurley JP, Salmaso S, Kale A, Tolcheva E, Levchenko TS, et al. “SMART” drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers. Bioconjug Chem. 2006;17(4):943–9.

    Article  Google Scholar 

  58. Saad M, Garbuzenko OB, Minko T. Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Nanomedicine (Lond). 2008;3(6):761–76.

    Article  Google Scholar 

  59. Han S, Mahato RI, Sung YK, Kim SW. Development of biomaterials for gene therapy. Mol Ther. 2000;2(4):302–17.

    Article  Google Scholar 

  60. Fadel TR, Sharp FA, Vudattu N, Ragheb R, Garyu J, Kim D, et al. A carbon nanotube-polymer composite for T-cell therapy. Nat Nanotechnol. 2014;9(8):639–47.

    Article  Google Scholar 

  61. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–22.

    Article  Google Scholar 

  62. Boudreau JE, Bonehill A, Thielemans K, Wan Y. Engineering dendritic cells to enhance cancer immunotherapy. Mol Ther. 2011;19(5):841–53.

    Article  Google Scholar 

  63. Brody JD, Engleman EG. DC-based cancer vaccines: lessons from clinical trials. Cytotherapy. 2004;6(2):122–7.

    Article  Google Scholar 

  64. Gilboa E. DC-based cancer vaccines. J Clin Invest. 2007;117(5):1195–203.

    Article  Google Scholar 

  65. Jahnisch H, Fussel S, Kiessling A, Wehner R, Zastrow S, Bachmann M, et al. Dendritic cell-based immunotherapy for prostate cancer. Clin Dev Immunol. 2010;2010:517493.

    Article  Google Scholar 

  66. Radford KJ, Tullett KM, Lahoud MH. Dendritic cells and cancer immunotherapy. Curr Opin Immunol. 2014;27:26–32.

    Article  Google Scholar 

  67. Kim J, Mooney DJ. In vivo modulation of dendritic cells by engineered materials: towards new cancer vaccines. Nano Today. 2011;6(5):466–77.

    Article  Google Scholar 

  68. Liu Y, Zhang W, Chan T, Saxena A, Xiang J. Engineered fusion hybrid vaccine of IL-4 gene-modified myeloma and relative mature dendritic cells enhances antitumor immunity. Leuk Res. 2002;26(8):757–63.

    Article  Google Scholar 

  69. Fang B, Roth JA. The role of gene therapy in combined modality treatment strategies for cancer. Curr Opin Mol Ther. 2003;5(5):475–82.

    Google Scholar 

  70. Fujiwara T, Grimm EA, Roth JA. Gene therapeutics and gene therapy for cancer. Curr Opin Oncol. 1994;6(1):96–105.

    Article  Google Scholar 

  71. Wadhwa PD, Zielske SP, Roth JC, Ballas CB, Bowman JE, Gerson SL. Cancer gene therapy: scientific basis. Annu Rev Med. 2002;53:437–52.

    Article  Google Scholar 

  72. Singh A, Suri S, Roy K. In-situ crosslinking hydrogels for combinatorial delivery of chemokines and siRNA-DNA carrying microparticles to dendritic cells. Biomaterials. 2009;30(28):5187–200.

    Article  Google Scholar 

  73. Singh A, Qin H, Fernandez I, Wei J, Lin J, Kwak LW, et al. An injectable synthetic immune-priming center mediates efficient T-cell class switching and T-helper 1 response against B cell lymphoma. J Control Release. 2011;155(2):184–92.

    Article  Google Scholar 

  74. Singh A, Nie H, Ghosn B, Qin H, Kwak LW, Roy K. Efficient modulation of T-cell response by dual-mode, single-carrier delivery of cytokine-targeted siRNA and DNA vaccine to antigen-presenting cells. Mol Ther. 2008;16(12):2011–21.

    Article  Google Scholar 

  75. Blau HM, Springer ML. Gene therapy–a novel form of drug delivery. N Engl J Med. 1995;333(18):1204–7.

    Article  Google Scholar 

  76. Kang DC, Gopalkrishnan RV, Wu Q, Jankowsky E, Pyle AM, Fisher PB. mda-5: an interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties. Proc Natl Acad Sci U S A. 2002;99(2):637–42.

    Article  Google Scholar 

  77. Rudzinski WE, Aminabhavi TM. Chitosan as a carrier for targeted delivery of small interfering RNA. Int J Pharm. 2010;399(1–2):1–11.

    Article  Google Scholar 

  78. Liu H, Moynihan KD, Zheng Y, Szeto GL, Li AV, Huang B, et al. Structure-based programming of lymph-node targeting in molecular vaccines. Nature 2014;507(7493):519–22.

    Article  Google Scholar 

  79. Pradhan P, Qin H, Leleux JA, Gwak D, Sakamaki I, Kwak LW, et al. The effect of combined IL10 siRNA and CpG ODN as pathogen-mimicking microparticles on Th1/Th2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma. Biomaterials 2014;35(21):5491–504.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sibley School of Mechanical and Aerospace Engineering, Cornell University, Ithaca, NY, 14853, USA

    Fnu Apoorva & Prof. Ankur Singh

Authors
  1. Fnu Apoorva
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Ankur Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ankur Singh .

Editor information

Editors and Affiliations

  1. Albert Einstein College of Medicine, Bronx, New York, USA

    Laura Santambrogio

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Apoorva, F., Singh, A. (2015). Biomaterial-Based Modulation of Cancer. In: Santambrogio, L. (eds) Biomaterials in Regenerative Medicine and the Immune System. Springer, Cham. https://doi.org/10.1007/978-3-319-18045-8_10

Download citation

Publish with us

Policies and ethics

Search

Navigation